×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
RARE – ultragenyx pharmaceutical inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
RARE
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
3/5
04:59 pm
rare
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Ultragenyx Pharmaceutical Inc. of Class Action Lawsuit and Upcoming Deadlines - RARE
Low
Report
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Ultragenyx Pharmaceutical Inc. of Class Action Lawsuit and Upcoming Deadlines - RARE
3/4
09:28 pm
rare
Ultragenyx Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against Ultragenyx Pharmaceutical Inc. - RARE
Low
Report
Ultragenyx Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against Ultragenyx Pharmaceutical Inc. - RARE
3/4
04:15 pm
rare
Ultragenyx Pharmaceutical Inc. Investors with Substantial Losses Have Opportunity to Lead Investor Class Action Lawsuit - RGRD Law
Low
Report
Ultragenyx Pharmaceutical Inc. Investors with Substantial Losses Have Opportunity to Lead Investor Class Action Lawsuit - RGRD Law
3/4
01:14 pm
rare
Robbins LLP Urges RARE Stockholders to Contact the Firm for Information About the Class Action Against Ultragenyx Pharmaceutical Inc.
Low
Report
Robbins LLP Urges RARE Stockholders to Contact the Firm for Information About the Class Action Against Ultragenyx Pharmaceutical Inc.
3/4
12:00 pm
rare
Bronstein, Gewirtz & Grossman LLC Urges Ultragenyx Pharmaceutical Inc. Investors to Act: Class Action Filed Alleging Investor Harm
Low
Report
Bronstein, Gewirtz & Grossman LLC Urges Ultragenyx Pharmaceutical Inc. Investors to Act: Class Action Filed Alleging Investor Harm
3/4
10:33 am
rare
UPCOMING DEADLINE: Ultragenyx Pharmaceutical Inc. (RARE) Securities Fraud Class Action – April 6, 2026 Lead Plaintiff Deadline - Furuqi & Furuqi LLP
Low
Report
UPCOMING DEADLINE: Ultragenyx Pharmaceutical Inc. (RARE) Securities Fraud Class Action – April 6, 2026 Lead Plaintiff Deadline - Furuqi & Furuqi LLP
3/4
09:00 am
rare
LEVI & KORSINSKY, LLP: RARE STOCK DECLINED OVER 42% FOLLOWING PHASE III STUDY FAILURE DISCLOSURE
Low
Report
LEVI & KORSINSKY, LLP: RARE STOCK DECLINED OVER 42% FOLLOWING PHASE III STUDY FAILURE DISCLOSURE
3/3
09:39 pm
rare
Ultragenyx Pharmaceutical Inc. Notice of April 6, 2026 Application Deadline for Class Action Lawsuit - Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline
Medium
Report
Ultragenyx Pharmaceutical Inc. Notice of April 6, 2026 Application Deadline for Class Action Lawsuit - Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline
Date
Time
Symbol
Company Name
Action
%Chg
2/12/2026
04:01 pm
RARE
ultragenyx pharmaceutical inc.
MISS
Report
-12.7%
ultragenyx pharmaceutical inc.
11/4/2025
04:05 pm
RARE
ultragenyx pharmaceutical inc.
MISS
Report
-1.8%
ultragenyx pharmaceutical inc.
8/5/2025
04:07 pm
RARE
ultragenyx pharmaceutical inc.
BEAT
Report
-4.9%
ultragenyx pharmaceutical inc.
5/6/2025
04:01 pm
RARE
ultragenyx pharmaceutical inc.
MISS
Report
-4.7%
ultragenyx pharmaceutical inc.
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
3/3
07:10 pm
rare
Form 4 Ultragenyx Pharmaceutica For: Mar 01 Filed by: Pinion John Richard
Medium
Report
Form 4 Ultragenyx Pharmaceutica For: Mar 01 Filed by: Pinion John Richard
3/3
07:08 pm
rare
Form 4 Ultragenyx Pharmaceutica For: Mar 01 Filed by: Harris Erik
Medium
Report
Form 4 Ultragenyx Pharmaceutica For: Mar 01 Filed by: Harris Erik
3/3
07:06 pm
rare
Form 4 Ultragenyx Pharmaceutica For: Mar 01 Filed by: KAKKIS EMIL D
Medium
Report
Form 4 Ultragenyx Pharmaceutica For: Mar 01 Filed by: KAKKIS EMIL D
3/3
06:52 pm
rare
Form 4 Ultragenyx Pharmaceutica For: Mar 02 Filed by: Huizenga Theodore Alan
Medium
Report
Form 4 Ultragenyx Pharmaceutica For: Mar 02 Filed by: Huizenga Theodore Alan
3/3
06:52 pm
rare
Form 4 Ultragenyx Pharmaceutica For: Mar 01 Filed by: Parschauer Karah Herdman
Medium
Report
Form 4 Ultragenyx Pharmaceutica For: Mar 01 Filed by: Parschauer Karah Herdman
3/3
06:50 pm
rare
Form 4 Ultragenyx Pharmaceutica For: Mar 01 Filed by: Crombez Eric
Medium
Report
Form 4 Ultragenyx Pharmaceutica For: Mar 01 Filed by: Crombez Eric
3/3
06:50 pm
rare
Form 4 Ultragenyx Pharmaceutica For: Mar 01 Filed by: Horn Howard
Medium
Report
Form 4 Ultragenyx Pharmaceutica For: Mar 01 Filed by: Horn Howard
3/3
06:49 pm
rare
Form 4 Ultragenyx Pharmaceutica For: Mar 01 Filed by: Huang Dennis Karl
Medium
Report
Form 4 Ultragenyx Pharmaceutica For: Mar 01 Filed by: Huang Dennis Karl
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
1/9
Ultragenyx Announces Positive Topline Cohort 3 Results and Improved Longer-Term Cohort 2 Results from Phase 1/2 Study of DTX301 Gene Therapy in Ornithine Transcarbamylase (OTC) Deficiency
23.4%
3/13 Form 4 Ultragenyx Pharmaceutica For: Mar 12 Filed by: KAKKIS EMIL D 10.2%
1/13 Ultragenyx and Kyowa Kirin Announce Submission of Supplemental Biologics License Application to U.S. FDA for Crysvita® (burosumab) for Tumor-Induced Osteomalacia (TIO) 8.1%
3/9 Ultragenyx to Present at Barclays Global Healthcare Conference 7.7%
4/2 Ultragenyx Pharmaceutical Inc (NASDAQ: RARE) had its "buy" rating re-affirmed by analysts at Robert W. Baird. They now have a $75.00 price target on the stock. 6.6%
6/17 Ultragenyx Expands Leadership Team and Promotes Erik Harris to Chief Commercial Officer 6.5%
3/31 REGENXBIO and Ultragenyx Announce New License Agreement for Use of NAV® Technology Platform for the Treatment of Rare Metabolic Disorder 5.7%
7/17 Form 4 Ultragenyx Pharmaceutica For: Jul 16 Filed by: Pinion John Richard 5.1%
9/11 Ultragenyx Pharmaceutical Inc (NASDAQ: RARE) was downgraded by analysts at BidaskClub from a "hold" rating to a "sell" rating. 4.4%
4/17 Ultragenyx Pharmaceutical Inc (NASDAQ: RARE) was upgraded by analysts at BidaskClub from a "hold" rating to a "buy" rating. 4.2%
3/13 Form 4 Ultragenyx Pharmaceutica For: Mar 12 Filed by: KAKKIS EMIL D 10.2%
1/13 Ultragenyx and Kyowa Kirin Announce Submission of Supplemental Biologics License Application to U.S. FDA for Crysvita® (burosumab) for Tumor-Induced Osteomalacia (TIO) 8.1%
3/9 Ultragenyx to Present at Barclays Global Healthcare Conference 7.7%
4/2 Ultragenyx Pharmaceutical Inc (NASDAQ: RARE) had its "buy" rating re-affirmed by analysts at Robert W. Baird. They now have a $75.00 price target on the stock. 6.6%
6/17 Ultragenyx Expands Leadership Team and Promotes Erik Harris to Chief Commercial Officer 6.5%
3/31 REGENXBIO and Ultragenyx Announce New License Agreement for Use of NAV® Technology Platform for the Treatment of Rare Metabolic Disorder 5.7%
7/17 Form 4 Ultragenyx Pharmaceutica For: Jul 16 Filed by: Pinion John Richard 5.1%
9/11 Ultragenyx Pharmaceutical Inc (NASDAQ: RARE) was downgraded by analysts at BidaskClub from a "hold" rating to a "sell" rating. 4.4%
4/17 Ultragenyx Pharmaceutical Inc (NASDAQ: RARE) was upgraded by analysts at BidaskClub from a "hold" rating to a "buy" rating. 4.2%
TOP News Decliners
3/16
GeneTx and Ultragenyx Announce First Patient Dosed in Phase 1/2 Clinical Trial of GTX-102 in Patients with Angelman Syndrome
-21.2%
9/4 Form 8-K Ultragenyx Pharmaceutica For: Sep 04 -13.3%
3/6 Form 8-K Ultragenyx Pharmaceutica For: Mar 03 -9.3%
8/1 Form 8-K Ultragenyx Pharmaceutica For: Aug 01 -9.0%
5/7 Form 10-Q Ultragenyx Pharmaceutica For: Mar 31 -7.0%
8/27 Ultragenyx Pharmaceutical Inc (NASDAQ: RARE) was downgraded by analysts at BidaskClub from a "buy" rating to a "hold" rating. -6.9%
3/6 Ultragenyx Pharmaceutical Inc (NASDAQ: RARE) was downgraded by analysts at BidaskClub from a "buy" rating to a "hold" rating. -6.8%
10/29 Ultragenyx Pharmaceutical Inc (NASDAQ: RARE) was downgraded by analysts at ValuEngine from a "buy" rating to a "hold" rating. -6.1%
11/5 Q3/2019 9/30/2019 EPS -1.960 ZacksConsensus -1.710 ActVsEst (0.250) - Miss -5.9%
9/3 GeneTx and Ultragenyx Announce Orphan Drug Designation and Rare Pediatric Disease Designation for GTX-102 -5.8%
9/4 Form 8-K Ultragenyx Pharmaceutica For: Sep 04 -13.3%
3/6 Form 8-K Ultragenyx Pharmaceutica For: Mar 03 -9.3%
8/1 Form 8-K Ultragenyx Pharmaceutica For: Aug 01 -9.0%
5/7 Form 10-Q Ultragenyx Pharmaceutica For: Mar 31 -7.0%
8/27 Ultragenyx Pharmaceutical Inc (NASDAQ: RARE) was downgraded by analysts at BidaskClub from a "buy" rating to a "hold" rating. -6.9%
3/6 Ultragenyx Pharmaceutical Inc (NASDAQ: RARE) was downgraded by analysts at BidaskClub from a "buy" rating to a "hold" rating. -6.8%
10/29 Ultragenyx Pharmaceutical Inc (NASDAQ: RARE) was downgraded by analysts at ValuEngine from a "buy" rating to a "hold" rating. -6.1%
11/5 Q3/2019 9/30/2019 EPS -1.960 ZacksConsensus -1.710 ActVsEst (0.250) - Miss -5.9%
9/3 GeneTx and Ultragenyx Announce Orphan Drug Designation and Rare Pediatric Disease Designation for GTX-102 -5.8%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: